PPT-Rivaroxaban or Aspirin for Extended Treatment of Venous Thr
Author : yoshiko-marsland | Published Date : 2017-12-09
EINSTEIN CHOICE Ryan Sparks PharmD BCPS PGY2 Cardiology Resident WakeMed Health amp Hosptials Raleigh NC Dr Ryan Sparks presenter Current PGY2 Cardiology Resident
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Rivaroxaban or Aspirin for Extended Trea..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Rivaroxaban or Aspirin for Extended Treatment of Venous Thr: Transcript
EINSTEIN CHOICE Ryan Sparks PharmD BCPS PGY2 Cardiology Resident WakeMed Health amp Hosptials Raleigh NC Dr Ryan Sparks presenter Current PGY2 Cardiology Resident at WakeMed. Alexander T Cohen . On behalf of the MAGELLAN Steering Committee and Investigators. Potential conflicts. Dr AT Cohen is a medical consultant for and has received honoraria, consultancy and clinical trial funding from many pharmaceutical companies, including: . Thromboembolism. N . Engl. J Med. 2012;366:1959-67. VTE Prevalence. Incidence . of DVT: 48 per 100,000. Incidence of PE: 23 per 100,000. Case-fatality rate. Inpatient: 12%. 1-year: 19%; 3-year: 30%. Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators. Committees and . D. isclosures. Academic Executive Committee. E. Magnus Ohman, MB - Co-chair. C. Michael Gibson, MS, MD - Co-chair. Matthew T. Roe, MD, MHS. Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators. Committees and . D. isclosures. Academic Executive Committee. E. Magnus Ohman, MB - Co-chair. C. Michael Gibson, MS, MD - Co-chair. Matthew T. Roe, MD, MHS. Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators. Committees and . D. isclosures. Academic Executive Committee. E. Magnus Ohman, MB - Co-chair. C. Michael Gibson, MS, MD - Co-chair. Matthew T. Roe, MD, MHS. Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial Kelley Branch, MD, MSc, on behalf of the COMPASS Steering Committee and Investigators Original Article Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism Timothy A. Brighton, M.B., B.S., John W. Eikelboom, M.B., B.S., Kristy Mann, M.Biostat., Rebecca Mister, M.Sc., Alexander Gallus, M.B., B.S., Paul Ockelford, M.B., Harry Gibbs, M.B., Wendy Hague, Ph.D., Denis Xavier, M.Sc., Rafael Diaz, M.D., Adrienne Kirby, M.Sc., John Simes, M.D., for the ASPIRE Investigators Dr. Phil Wells on behalf of the EINSTEIN CHOICE Steering Committee and Investigators Weitz JI et al. N Engl J Med 2017 ( In Press) Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism Primary Prevention ASCVD. Jennifer Bannon RN BSN MSHI. Table of Contents. Objectives . Cardiovascular Disease. Cardiovascular Disease (2). ABCS-Aspirin when appropriate. Anatomy of a Performance Measure. Sonia Anand, on . behalf of the COMPASS Steering Committee and . Investigators. 17-07-01. August 27, 2017. COMPASS PAD rationale. PAD patients have . widespread atherosclerosis . and increased . risk of . Kourosh. . Sadeghi. Tehran University of medical sciences. New Oral Anticoagulants (NOACs). Available in Iran. NOACs. Clinical Trials. RE-LY Study. 951 . clinical . centers in . 44 . countries, . Non-inferiority trial, 18,113 patients, fixed doses of dabigatran 110 mg or 150 mg twice daily — or, in an un-blinded fashion, adjusted-dose warfarin. . CrCl. : creatinine clearance, CTO: chronic total occlusion, DAPT: dual antiplatelet therapy, DOAC: direct oral anticoagulant, . eDAN. : electronic discharge advice notification, GFR: glomerular filtration rate, HF: heart failure, INR: international normalised ratio, LHP: Leeds Health Pathways, LTHT: Leeds Teaching Hospitals NHS Trust, LV: left ventricular, MACE: major adverse cardiovascular event, MI: myocardial infarction, NICE: National Institute for Health and Care Excellence, NSTEMI: non-ST segment elevation myocardial infarction, STEMI: ST segment elevation myocardial infarction, OD: once daily, PAD: peripheral arterial disease, P2Y12: platelet receptor for adenosine diphosphate PCI: percutaneous coronary intervention, PPI: proton pump inhibitor, SPC: summary of product characteristics, TIA: transient ischaemic attack.. and . arterial. . thrombosis. Walter Ageno. Department of Clinical Medicine. University of Insubria. Varese - Italy. Asymptomatic atherosclerosis . and deep vein thrombosis. . A. therosclerosis. . karim. Roosevelt University . Definition/Signs and Symptoms. Deep vein thrombosis (DVT) – blood clot occurring in a deep vein. Classified as distal or proximal. Pulmonary embolism (PE) – blood clot occurring in artery of the lung.
Download Document
Here is the link to download the presentation.
"Rivaroxaban or Aspirin for Extended Treatment of Venous Thr"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents